Aligos Therapeutics (ALGS) Projected to Post Earnings on Tuesday

Aligos Therapeutics (NASDAQ:ALGS) is anticipated to release its Q1 2025 earnings data before the market opens on Tuesday, May 6th. Analysts expect Aligos Therapeutics to post earnings of ($2.80) per share and revenue of $0.33 million for the quarter.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings results on Monday, March 10th. The company reported ($13.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.63) by ($10.45). Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%. The business had revenue of $0.63 million for the quarter, compared to analyst estimates of $0.43 million. During the same period in the previous year, the company posted ($5.50) earnings per share. On average, analysts expect Aligos Therapeutics to post $-10 EPS for the current fiscal year and $-12 EPS for the next fiscal year.

Aligos Therapeutics Trading Down 7.1 %

Shares of ALGS opened at $5.60 on Friday. Aligos Therapeutics has a 12 month low of $3.76 and a 12 month high of $46.80. The stock has a fifty day moving average price of $8.54 and a 200-day moving average price of $19.41. The firm has a market cap of $34.24 million, a PE ratio of -0.42 and a beta of 2.72.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $70.00 price target on shares of Aligos Therapeutics in a report on Monday, March 31st.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).